Emil D. Kakkis - 09 Dec 2024 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Signature
/s/ Karah Parschauer, attorney-in-fact
Issuer symbol
RARE
Transactions as of
09 Dec 2024
Net transactions value
-$413,650
Form type
4
Filing time
11 Dec 2024, 18:44:06 UTC
Previous filing
05 Sep 2024
Next filing
31 Dec 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Gift $0 -20,000 -0.9% $0.000000 2,203,985 09 Dec 2024 By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009
transaction RARE Common Stock Sale $413,650 -8,273 -0.38% $50.00 2,195,712 10 Dec 2024 By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009
holding RARE Common Stock 564,605 09 Dec 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F2 Includes 8 shares acquired under the Company's A&R 2014 Employee Stock Purchase Plan on October 31, 2024.